Latest Depression News

Page 1 of 14
Microequities’ funds under management fell to approximately $473 million by 31 October as weak small-cap valuations continued to pressure earnings. The funds manager plans to deploy more balance-sheet capital while developing a new fixed income trust.
Claire Turing
Claire Turing
19 Nov 2026
Kingsland Minerals ended the September quarter with $752,000 in cash and estimated funding for less than one quarter at current outgoings. Discussions with major shareholder Quinbrook remain non-binding, while the company has paused Leliyn exploration and is considering drilling its gold and uranium projects.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Glencore delivered a stronger third quarter across several key commodities and expects 2026 Marketing Adjusted EBIT to exceed $5 billion. Copper production improved on a like-for-like basis, while ferrochrome output climbed as South African smelters restarted.
Victor Sage
Victor Sage
29 Oct 2026
Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.
Ada Torres
Ada Torres
28 Oct 2026
Amotiv has cut its FY27 revenue and underlying EBITA outlook by up to 5% after first-quarter revenue fell 5% on weaker vehicle demand and Thailand flooding. The ASX-listed automotive parts group will nevertheless launch another buyback of up to 5% of its shares, betting its depressed valuation will recover.
Victor Sage
Victor Sage
27 Oct 2026
Temple & Webster is holding to its FY27 EBITDA target of $33 million to $40 million even as revenue fell 8% in the first months of the year. The online retailer says reduced discounting is depressing sales but improving contribution margins, while AI, private-label products and brand investment move from testing into rollout.
Logan Eniac
Logan Eniac
23 Oct 2026
Cogstate secured US$25.1 million in new sales contracts during 1Q27, including five Phase 3 bipolar and depression trials that accounted for more than 80% of quarterly contract value. Total contracted revenue reached US$143.7 million, although the quarter produced a lower-than-usual near-term revenue yield.
Victor Sage
Victor Sage
12 Oct 2026
Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.
Victor Sage
Victor Sage
9 Oct 2026
TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.
Ada Torres
Ada Torres
29 Sept 2026
Nico Resources is advancing drilling, metallurgical studies and a potential downstream battery-materials partnership at Wingellina, despite a subdued nickel market and a larger annual loss. The company ended FY2026 with $4.73 million across cash and short-term investments after raising $3.73 million in equity.
Maxwell Dee
Maxwell Dee
25 Sept 2026
Entropy Neurodynamics reported that all six patients in Cohort 1 of its Phase 2 BED trial maintained clinically meaningful improvement 12 weeks after two TRP-8803 infusions. Three patients experienced no binge-eating episodes during the 84-day follow-up, although the results come from a small, open-label study without a control group.
Ada Torres
Ada Torres
14 Sept 2026
Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.
Ada Torres
Ada Torres
10 Sept 2026

Browse the archive

Full archive